News

Pfizer's $43B Seagen deal strengthens its oncology portfolio, offsets patent cliffs, and offers 70%+ upside potential. See ...
Pfizer got a reprieve in late January when Starboard didn’t nominate its own slate of directors to the company’s board, but the activist could still agitate for changes in 2026.
According to Starboard Value LP, Pfizer Inc. (NYSE:PFE) has erased more than $20 billion in market value since 2019 despite receiving $40 billion from the sale of Covid 19 vaccines.
Pfizer is facing another setback with its weight-loss pill, danuglipron. The pharmaceutical giant stopped development of the drug after liver issues affected one patient.
Capping more than two years of stock-gyrating drama, Pfizer said Monday that it would stop development of danuglipron, its experimental oral GLP-1 medicine to treat obesity.
To put Pfizer's deal in perspective, rival Merck & Co. Inc. (MRK) had announced in November 2024 a licensing deal with Shanghai-based LaNova Medicines Ltd. for PD-1/VEGF antibody LM-299, in which ...
Pfizer said on Monday it has discontinued development of experimental weight-loss pill danuglipron after a trial patient experienced potential drug-induced liver injury that resolved after the ...
Pfizer jumps into cancer-treatment race with a $6 billion licensing deal with a China-based company, six months after Merck’s move for a lot less money.